Vericel
Manufacturing · Massachusetts, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
64 Sidney St, Cambridge, Massachusetts, ...Phone Number
(617) 588-5555Website
www.vcel.comRevenue
$292.1 MillionStock Symbol
VCELIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About Vericel
Vericel Corporation is a commercial-stage biopharmaceutical company incorporated in 1989 and headquartered in Cambridge, Massachusetts, focused on the development, manufacture, and commercialization of advanced cell therapies and specialty biologic products. The company serves the sports medicine and severe burn care markets in North America, offering a portfolio of autologous cell therapy products and a licensed specialty biologic for burn treatment. Its products are sold through orthopedic surgeons, sports medicine specialists, and specialized burn care centers across the United States. Vericel combines innovations in cell biology with medical technology to deliver differentiated therapies that repair injuries and address serious medical conditions. The company was formerly known as Aastrom Biosciences, Inc. and adopted its current name in November 2014. Vericel trades on the NASDAQ under the ticker symbol VCEL.Explore more
Vericel Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Vericel your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Vericel has new funding data
Check out if Vericel is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Vericel has recently received funding, and reach out quickly before it becomes old news!
Vericel, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Vericel recently announced quarterly report
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Vericel launches new products
Click to see if Vericel had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Vericel
Recommended Actions
Reach out to Masked Content who joined Vericel as Masked Content
Find 3 more new buyers
Compare Similar Companies to Vericel
Compare insights from companies similar to Vericel, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Vericel is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Vericel is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Vericel.
Vericel financials insights
Gather financial insights about Vericel, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Stock Offering
$12.4M
Stock Offering
$20.5M
2012
Share Placement
$38M
2013
Stock Offering
$9M
2014
Private Equity
$15M
Stock Offering
$40.3M
2016
Stock Offering
$20M
2017
Debt
$25M
2018
Stock Offering
$74.8M
Vericel Tech Stack
A closer look at the technologies used by Vericel
See more technologies
Most Recent Scoops
Person-Based
Forecasting
Person-Based
Earnings, Finance, Financial Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Earnings
Vericel has indicated that a 20%+ intermediate-to-longer-term MACI revenue growth rate is a reasonable expectation, driven by a combination of high single-digit to low double-digit annual pricing growth and close to double-digit unit volume growth, supported by low market penetration and the absence of MACI-like competition on the horizon.
Earnings, Pharmaceuticals, Finance, Pricing
Earnings
Earnings, Forecasting, Finance
Vericel News & Media
Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026
BURLINGTON, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its second quarter 2026 financial results on Thursday, July 30, 2026. Vericel’s management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.Vericel Stock Is Up 10%. Here's What This $402,000 Insider Sale Really Suggests
Focused on regenerative therapies for sports medicine and burn care, this biopharma firm reported a notable insider sale in June.Regenerative Medicine’s Next Chapter: Inside the Race to Make the Body Rebuild Itself
Issued on behalf of Conexeu Sciences Inc.The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It
Issued on behalf of Conexeu Sciences Inc.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Vericel
Sign Up For FreeTo access detailed company insights
Vericel Corporation is a commercial-stage biopharmaceutical company incorporated in 1989 and headquartered in Cambridge, Massachusetts, focused on the development, manufacture, and commercialization of advanced cell therapies and specialty biologic products. The company serves the sports medicine and severe burn care markets in North America, offer... Read More
